Shares of Portola Pharmaceuticals more than doubled on news that Boston-based Alexion Pharmaceuticals is acquiring the company and Portola’s blood-disorder assets for $1.41 billion in cash.

Daiichi Sankyo Europe GmbH announced that the European Committee for Medicinal Products for Human Use (CHMP) recommended approval of a label update for the company’s oral, once-daily direct factor Xa-inhibitor Lixiana, to provide guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion (treatment to restore a normal heart rhythm).

Portola Pharmaceuticals announced that the U.S. Food and Drug Administration rejected its AndexXa to treat life-threatening or uncontrolled bleeding.

A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective in a late […]